Sun Pharmaceuticals advanced over 2% to Rs 1,188. The stock touched an intra-day high of Rs 1,189 and a low of Rs 1,180. Around 25,900 shares changed hands at the counter as against its two-week average traded quantity of 33,712 shares.
____________________________________________________________
(Updated 1025 hrs)
Sun Pharma has gained over 2% on winning a patent challenge.
The stock opened at Rs 1,189 and surged 3% to touch a high of Rs 1,201. The stock is now trading with 2% gain at Rs 1,190. Around 6,312 shares have been traded on the BSE so far.
Sun Pharma has successfully won a patent challenge of Eli Lilly's popular cancer medicine, Gemzar, in US. The company would now be able to produce a low-cost version of the same medicine in the world's largest drug market. Gemzar is Lilly's fourth best-selling drug and had worldwide sales worth $721 million for the first six months of 2009.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app